A new drug, ISM5411, developed using generative AI by Insilico Medicine’s Chemistry42 platform, has shown promising results in phase I trials for treating inflammatory bowel disease (IBD). Published in Nature Biotechnology, the study highlights ISM5411’s favorable pharmacokinetics (PK) and gut-restrictive properties, demonstrating low systemic exposure and a high fecal/plasma ratio, which is critical for localized GI treatments.
Keep Reading
Add A Comment